Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research

Michael J. Morris, Ethan M. Basch, George Wilding, Maha Hussain, Michael A. Carducci, Celestia Higano, Philip Kantoff, William K. Oh, Eric J. Small, Daniel George, Paul Mathew, Tomasz M. Beer, Susan E. Slovin, Charles Ryan, Christopher Logothetis, Howard I. Scher

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Background: In 2005, the US Department of Defense, through the US Army Medical Research and Materiel Command, Office of the Congressionally Directed Medical Research Programs, created a funding mechanism to form a clinical trials consortium to conduct phase I and II studies in prostate cancer. This is the first report of the Prostate Cancer Clinical Trials Consortium (PCCTC). Patients and Methods: The Department of Defense award supports a consortium of 10 prostate cancer research centers. Memorial Sloan-Kettering Cancer Center was awarded the Coordinating Center grant for the consortium and charged with creating an infrastructure to conduct early-phase multicenter clinical trials. Each participating center was required to introduce ≥ 1 clinical trial per year and maintain accrual of a minimum of 35 patients per year. Results: The PCCTC was launched in 2006 and now encompasses 10 leading prostate cancer research centers. Fifty-one trials have been opened, and 1386 patients have been accrued at member sites. Members share an online clinical trial management system for protocol tracking, electronic data capture, and data storage. A legal framework has been instituted, and standard operating procedures, an administrative structure, editorial support, centralized budgeting, and mechanisms for scientific review are established. Conclusion: The PCCTC fulfills a congressional directive to create a clinical trials instrument dedicated to early-phase prostate cancer studies. The member institutions have built an administrative, informatics, legal, financial, statistical, and scientific infrastructure to support this endeavor. Clinical trials are open and accruing in excess of federally mandated goals.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalClinical Genitourinary Cancer
Issue number1
StatePublished - 2009
Externally publishedYes

Bibliographical note

Funding Information:
This study is supported by the US Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. The authors wish to thank Mary Warren, MSW; Jake Vinson, MHA; Moshe Kelsen; Elizabeth Brand; and Hope J. Lafferty, MA, ELS, of the PCCTC for their assistance in preparing this manuscript.


  • Clinical consortium
  • Collaborative
  • Infrastructure
  • Phase I/II trial


Dive into the research topics of 'Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research'. Together they form a unique fingerprint.

Cite this